| Market Cap | 6.41M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -5.07M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -7.00% |
| Sales | 249k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -42.00% |
| Dividend | N/A | Price/Book | 0.78 | EPS next 5Y | - | 52W High Chg | -80.00% |
| Recommedations | - | Quick Ratio | 1.51 | Shares Outstanding | 57.17M | 52W Low Chg | - |
| Insider Own | 20.33% | ROA | -37.91% | Shares Float | 46.71M | Beta | 0.67 |
| Inst Own | 21.40% | ROE | -106.77% | Shares Shorted/Prior | -/- | Price | 0.07 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 51 | Target Price | - |
| Oper. Margin | -2,101.91% | Earnings Date | May 23 | Volume | 3,216 | Change | 0.00% |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.